Long-term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma
In R/R MM after auto-HCT, allo-HCT for patients who attained CR following less than three lines of chemotherapy can still be a promising treatment option with long-term survival.
Authors
- Joon Young Hur (ORCID: https://orcid.org/0000-0003-0092-8370)
- Hyunkyung Park (ORCID: https://orcid.org/0000-0002-5646-8054)
- Eun-Hye Hur (ORCID: https://orcid.org/0000-0002-8613-4223)
- Seungah Cha (ORCID: https://orcid.org/0009-0005-1534-8979)
- Yunsuk Choi
- Sun-Hye Ko (ORCID: https://orcid.org/0000-0003-3387-3986)
- Yu-eun Lee
- Hyeran Kang
- Ji Min Woo
- YOUNG-AH KANG
- HAN-SEUNG PARK
- MIJIN JEON
- YOUNG-SHIN LEE
- JISOO JEONG
- JE-HWAN LEE
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
Publication Details
- Journal
- In Vivo
- Published
- 2026-02-27
- DOI
- https://doi.org/10.21873/invivo.14256
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00